ESPR
Price
$2.65
Change
+$0.09 (+3.52%)
Updated
Sep 26 closing price
Capitalization
534.3M
38 days until earnings call
SUPN
Price
$47.03
Change
-$0.15 (-0.32%)
Updated
Sep 26 closing price
Capitalization
2.64B
44 days until earnings call
Interact to see
Advertisement

ESPR vs SUPN

Header iconESPR vs SUPN Comparison
Open Charts ESPR vs SUPNBanner chart's image
Esperion Therapeutics
Price$2.65
Change+$0.09 (+3.52%)
Volume$5.4M
Capitalization534.3M
Supernus Pharmaceuticals
Price$47.03
Change-$0.15 (-0.32%)
Volume$594.77K
Capitalization2.64B
ESPR vs SUPN Comparison Chart in %
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. SUPN commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a StrongBuy and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (ESPR: $2.65 vs. SUPN: $47.03)
Brand notoriety: ESPR and SUPN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ESPR: 82% vs. SUPN: 71%
Market capitalization -- ESPR: $534.3M vs. SUPN: $2.64B
ESPR [@Pharmaceuticals: Generic] is valued at $534.3M. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.64B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ESPR and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).

  • ESPR’s TA Score: 4 bullish, 5 bearish.
  • SUPN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both ESPR and SUPN are a bad buy in the short-term.

Price Growth

ESPR (@Pharmaceuticals: Generic) experienced а -0.38% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +2.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.18%. For the same industry, the average monthly price growth was +24.24%, and the average quarterly price growth was +67.33%.

Reported Earning Dates

ESPR is expected to report earnings on Nov 05, 2025.

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.18% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($2.64B) has a higher market cap than ESPR($534M). SUPN YTD gains are higher at: 30.061 vs. ESPR (20.455). SUPN has higher annual earnings (EBITDA): 174M vs. ESPR (-32.5M). SUPN has more cash in the bank: 523M vs. ESPR (86.1M). SUPN has less debt than ESPR: SUPN (31.8M) vs ESPR (302M). SUPN has higher revenues than ESPR: SUPN (665M) vs ESPR (268M).
ESPRSUPNESPR / SUPN
Capitalization534M2.64B20%
EBITDA-32.5M174M-19%
Gain YTD20.45530.06168%
P/E RatioN/A40.90-
Revenue268M665M40%
Total Cash86.1M523M16%
Total Debt302M31.8M950%
FUNDAMENTALS RATINGS
ESPR vs SUPN: Fundamental Ratings
ESPR
SUPN
OUTLOOK RATING
1..100
8529
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
10081
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for SUPN (78) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than ESPR’s over the last 12 months.

SUPN's SMR Rating (81) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (36) in the Biotechnology industry is in the same range as SUPN (40) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SUPN’s over the last 12 months.

ESPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRSUPN
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 14 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSMVX18.200.17
+0.94%
Jackson Square SMID-Cap Growth Inv
RDLCX10.510.06
+0.57%
Columbia Disciplined Growth C
RIGIX44.530.25
+0.56%
American Funds Intl Gr and Inc R5E
NGDAX32.760.12
+0.37%
Neuberger Berman Large Cap Growth A
LMRNX33.670.12
+0.36%
1919 Socially Responsive Balanced I

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and DRRX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and DRRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
-0.32%
DRRX - SUPN
32%
Poorly correlated
N/A
DVAX - SUPN
29%
Poorly correlated
+0.51%
SNDL - SUPN
27%
Poorly correlated
-5.28%
ACET - SUPN
27%
Poorly correlated
+0.14%
ESPR - SUPN
26%
Poorly correlated
+3.52%
More